Defining cases of severe pediatric diarrhea for an efficacy trial of an enterotoxigenic Escherichia coli (ETEC) vaccine: Report on an international workshop, Washington DC, March 2016

Vaccine

Volumn 35, Issue 4, 2017, Pages 503-507

  Wierzba, Thomas F ^a   Bourgis, Alexandra ^a  

^a PATH   (United States)

Author keywords

Diarrhea; ETEC; Score; Severity; Vaccines

Indexed keywords

ESCHERICHIA COLI VACCINE;

CHILDHOOD DISEASE; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; ENTEROTOXIGENIC ESCHERICHIA COLI; HUMAN; PRIORITY JOURNAL; WORKSHOP; EDUCATION; ESCHERICHIA COLI INFECTION; IMMUNOLOGY; PATHOLOGY; SEVERITY OF ILLNESS INDEX; WASHINGTON;

DIARRHEA; EDUCATION; ENTEROTOXIGENIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI VACCINES; HUMANS; SEVERITY OF ILLNESS INDEX; WASHINGTON;

EID: 85009188247     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.12.006     Document Type: Conference Paper

References (19)

1. [1] Kotloff, K.L., Nataro, J.P., Blackwelder, W.C., Nasrin, D., Farag, T.H., Panchalingam, S., et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 382 (2013), 209–222.
2. [2] Lanata, C.F., Fischer-Walker, C.L., Olascoaga, A.C., Torres, C.X., Aryee, M.J., Black, R.E., et al. Global causes of diarrheal disease mortality in children <5 years of age: a systematic review. PLoS ONE, 8, 2013, e72788.
3. [3] Lamberti, L.M., Bourgeois, A.L., Fischer Walker, C.L., Black, R.E., Sack, D., Estimating diarrheal illness and deaths attributable to Shigellae and enterotoxigenic Escherichia coli among older children, adolescents, and adults in South Asia and Africa. PLoS Negl Trop Dis, 8, 2014, e2705.
4. [4] Svennerholm, A.M., Tobias, J., Vaccines against enterotoxigenic Escherichia coli. Expert Rev Vaccines 7 (2008), 795–804.
5. [5] Zhang, W., Sack, D.A., Progress and hurdles in the development of vaccines against enterotoxigenic Escherichia coli in humans. Expert Rev Vaccines 11 (2012), 677–694.
6. [6] Bourgeois, A.L., Wierzba, T.F., Walker, R.I., Status of vaccine research and development for enterotoxigenic Escherichia coli. Vaccine 34:26 (2016), 2880–2886.
7. [7] Lundgren, A., Bourgeois, L., Carlin, N., Clements, J., Gustafsson, B., Hartford, M., et al. Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study. Vaccine 32 (2014), 7077–7084.
8. [8] Savarino SJ. Field efficacy trial of an oral killed ETEC/rCTB vaccine in egyptian infants and young children. The sixth annual conference on vaccine research: basic science, product development, clinical and field studies. Arlington, Virginia; 5–7 May 2003.
9. [9] Sack, D.A., Shimko, J., Torres, O., Bourgeois, A.L., Francia, D.S., Gustafsson, B., et al. Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico. Vaccine 25 (2007), 4392–4400.
10. [10] Ruuska, T., Vesikari, T., Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 22 (1990), 259–267.
11. [11] Streiner, D.L., Norman, G.R., Health measurement scales: a practical guide to their development and use. 4th ed., 2008, Oxford University Press, Oxford.
12. [12] Apgar, V., A proposal for a new method of evaluation of the newborn infant. Curr Res Anesth Anal 32 (1953), 260–267.
13. [13] Casey, B.M., McIntire, D.D., Leveno, K.J., The continuing value of the Apgar score for the assessment of newborn infants. N Engl J Med 344 (2001), 467–471.
14. [14] World Health Organzation. Unicef handbook: IMCI integrated management of childhood illness. Geneva: World Health Organization; 2005. < http://apps.who.int/iris/bitstream/10665/42939/1/9241546441.pdf> (last accessed: 12/02/16).
15. [15] World Health Organization. Generic protocol for monitoring impact of rotavirus vaccination of gastroenteritis disease burden and viral strains. Geneva: World Health Organzation; 2008. < http://apps.who.int/iris/bitstream/10665/69913/1/WHO_IVB_08.16_eng.pdf> (last accessed: 12/02/2016).
16. [16] Lewis K. Vesikari clinical severity scoring system manual. PATH; 2011. < http://www.path.org/publications/files/VAD_vesikari_scoring_manual.pdf> (last accessed: 12/02/2016).
17. [17] Freedman, S.B., Eltorky, M., Gorelick, M., Pediatric emergency research canada gastroenteritis study G. evaluation of a gastroenteritis severity score for use in outpatient settings. Pediatrics 125 (2010), e1278–e1285.
18. [18] Schnadower, D., Tarr, P.I., Gorelick, M.H., O'Connell, K., Roskind, C.G., Powell, E.C., et al. Validation of the modified Vesikari score in children with gastroenteritis in 5 US emergency departments. J Pediatr Gastroenterol Nutr 57 (2013), 514–519.
19. [19] Platts-Mills, J.A., Babji, S., Bodhidatta, L., Gratz, J., Haque, R., Havt, A., et al. Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). Lancet Glob Health 3 (2015), e564–e575.